Human Microbiome Market is expected to exhibit a CAGR of 18.9% And to be valued at US$ 306,351.2 Mn in 2028 | ENTEROME SA, Embion Technologies S.A, IGEN BIOLAB GROUP

Overview:

Human microbiome plays a major role in modern healthcare. The microbiome is the genetic material of all the microbes, such as bacteria, fungi, protozoa and viruses, live on and inside the human body. Human microbiome help digest food, protect against other bacteria that cause disease, regulate immune system, and produce vitamins needed for blood coagulation.

Request Here For PDF Brochure With Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/182

Drivers:

Increasing funding for research institutes and microbiome companies is expected to boost the growth of the global human microbiome market over the forecast period. Multinational pharma companies, as well as investment firms, are financially supporting small biotech companies. For instance, in January 2018, Gnubiotics Sciences SA, a Swiss biotech company dedicated to revolutionizing microbiome health in both humans and animals, raised US$ 2.3 million through convertible debt with private investors and seeks to commercialize its first product candidate. The company is developing a platform to commercialize microbiome modulating products for the functional and medical nutrition markets.

Moreover, increase in research and development activities is expected to augment the growth of the global human microbiome market. For instance, in 2018, 4D Pharma announced positive results for its Phase Ib study of Thetanix in paediatric patients with Crohn’s disease.

Furthermore, market players are focusing on launching novel products in the market, which in turn is also expected to propel growth of the market. For instance, in November 2020, Beroni Group announced the launch of Beilemei in China. Beilemei is a probiotics health product aimed at modulating the balance of human intestinal flora.

Get Sample Report With Latest Covid19 Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/182

COVID-19 Impact:

The outbreak of COVID-19 (global pandemic) around the world is also expected to aid in the growth of the global human microbiome market. In March 2020, World Health Organization (WHO) declared COVID-19 (coronavirus) as a pandemic. According to WHO, worldwide, as of 11 May 2021, there have been 5.5 million confirmed cases of COVID-19, including 90,000 deaths. The first case of COVID-19 was reported in Wuhan, China in December 2019.

The pandemic has affected the supply chain of the medical food industry mainly due to the stringent measures imposed by the governments of several countries to curb the spread of the virus. However, according to the article published in May 2020 in the International Journal of Microbiology, probiotics have a positive impact on the immune response, and thus, probiotics use has increased during the pandemic as the virus directly affects the human immune system. Thus, there is an increasing demand for probiotics worldwide.

Key Players:

Key players active in the global human microbiome market are Assembly Biosciences, Inc., Seres Therapeutics, Inc., Rebiotix Inc., Vedanta Biosciences, Inc., AOBiome, Immuron Ltd., OxThera AB, Osel Inc., ViThera Pharmaceuticals Inc., YSOPIA Bioscience, 4D Pharma Plc., Ferring Pharmaceuticals, Gnubiotics Sciences, Evelo Biosciences Inc., Embion Technologies S.A, ENTEROME SA, IGEN BIOLAB GROUP, Finch Therapeutics Group, Inc. and Second Genome Therapeutics, among others.

Direct Purchase This Report @ https://www.coherentmarketinsights.com/insight/buy-now/182

Reasons to Purchase This Report

• Current and future of Human Microbiome Market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players

Table of Contents

1. Research Objectives and Assumptions
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Overview
   • Report Description
     • Market Definition and Scope
   • Executive Summary
     • Market Snippet, By Product Type
     • Market Snippet, By Disease Indication
     • Market Snippet, By Distribution Channel
     • Market Snippet, By Region
   • Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
   • Impact Analysis
   • Pipeline Analysis
   • Mergers, Acquisitions and Collaborations
   • Recent Product Launches
   • Regulatory Scenario
   • PEST Analysis
   • Epidemiology
   • Fecal Microbiota Transplantation (FMT)
4.  Global Human Microbiome Market – Impact of Coronavirus (Covid-19) Pandemic
   
   • COVID-19 Epidemiology
   • Impact on Demand and Supply Chain
   • Key Developments in Human Microbiome Market
   • Government Initiatives during COVID-19
5. Global Human Microbiome Market, By Product Type, 2017-2028 (US$ Million)
   • Introduction
     • Market Share Analysis, 2020 and 2027 (%)
     • Y-o-Y Growth Analysis, 2017 – 2027
     • Segment Trends
   • Foods
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
       • Prebiotics
       • Probiotics
       • Medical Foods
     • Fecal Microbiota Transplant (FMT)
       • Introduction
       • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
     • Microbiome Drugs
       • Introduction
       • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
     • Others
       • Introduction
       • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
6. Global Human Microbiome Market, By Disease Indication, 2017 – 2028 (US$ Million)
   • Introduction
     • Market Share Analysis, 2020 and 2027 (%)
     • Y-o-Y Growth Analysis, 2017 – 2027
     • Segment Trends
   • Clostridium Difficile Infection (CDI)
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
   • Inflammatory Bowel Disease (IBD)
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
   • Metabolic Disorders
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
   • Autoimmune Disorders
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
   • Allergic Diseases
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
   • Others
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
7. Global Human Microbiome Market, By Distribution Channel, 2017 – 2028 (US$ Million)
   • Introduction
     • Market Share Analysis, 2020 and 2027 (%)
     • Y-o-Y Growth Analysis, 2017 – 2027
     • Segment Trends
   • Hospital Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
   • Retail Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
   • Online Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
8. Global Human Microbiome Market, By Region, 2017 – 2028 (US$ Million)
   • Introduction
     • Market Share Analysis, By Region, 2020 and 2027 (%)
     • Y-o-Y Growth Analysis, For Regions, 2017 – 2027
     • Regional Trends
   • North America
     • Market Size and Forecast, By Product Type, 2017 – 2028 (US$ Mn)
     • Market Size and Forecast, By Disease Indication, 2017 – 2028 (US$ Mn)
     • Market Size and Forecast, By Distribution Channel, 2017 – 2028 (US$ Mn)
     • Market Size and Forecast, By Country, 2017 – 2028 (US$ Mn)
       • U.S.
       • Canada
   • Latin America
     • Brazil
     • Mexico
     • Argentina
     • Rest of Latin America
   • Europe
     • Germany
     • U.K.
     • France
     • Italy
     • Spain
     • Russia
     • Rest of Europe
   • Asia Pacific
     • China
     • India
     • Japan
     • Australia
     • South Korea
     • ASEAN
     • Rest of Asia Pacific
   • Middle East
     • GCC
     • Israel
     • Rest of Middle East
   • Africa
     • South Africa
     • Central Africa
     • North Africa